Supporting Pet Cancer Awareness Month with Reliable Logistics that Empower Breakthroughs
Every November, Pet Cancer Awareness Month serves as a reminder of the growing need for innovation and collaboration in the fight against cancer in companion animals. As cancer diagnoses in companion animals rise, so does the demand for advanced therapeutics, from monoclonal antibodies to cell therapies and everything in between. But innovation alone isn’t enough, these therapies are only as effective as the supply chains that support them.
For animal pharmaceutical companies and veterinary clinics, the ability to deliver temperature-sensitive, high-value treatments safely and on time has quickly become mission-critical. At Cryoport Systems, we specialize in logistics solutions that meet the rigorous and specialized demands of veterinary oncology, helping our partners to scale innovation while protecting product integrity and patient outcomes. We understand that innovation in veterinary oncology doesn’t stop at the lab bench; it must be matched by logistics infrastructure that can protect sensitive therapies.
A New Era of Cancer Care
The animal health industry is entering a new era of cancer care. From autologous cell therapies to temperature-sensitive biologics, the complexity of veterinary oncology treatments is increasing rapidly. These aren’t shelf-stable products that can sit in a stockroom. They’re fragile, high-value therapies that require precise environmental control and continuous monitoring from origin to administration.
For animal pharmaceutical companies, this means that your logistics provider is a strategic choice more than a back-office administrative task. And for veterinary clinics, it means that you need confidence that the therapies arriving at your door are viable and ready to administer. A delayed shipment or temperature excursion, a broken chain of custody… issues and errors for advanced therapeutics aren’t minor inconveniences. They’re potential treatment failures. In oncology, where timing and integrity are everything, the margin for error is razor-thin.
Cryoport Systems eliminates that margin. Our validated shipping systems are engineered to maintain strict temperature ranges throughout the entire journey. Every shipment is tracked with GPS and condition monitoring, for full (auditable) visibility into location, temperature, and handling throughout the journey. And our team of logistics experts stand ready to intervene should anything unforeseen occur during transit.
From Clinical Trials to Commercial Launch, Support That Scales
Whether you’re running a multi-site veterinary oncology trial or preparing for commercial distribution of a new therapy, Cryoport Systems is built to scale. We support animal health companies from early-stage development to market launch, ensuring that logistics never become a bottleneck to innovation.
Our Chain of Compliance® platform provides end-to-end traceability, helping you meet regulatory requirements and maintain product integrity. And our global infrastructure means you can expand into new markets with confidence.
Veterinary professionals are increasingly being asked to do more with less… more advanced care, more complex therapies, more patient volume. But they can’t do it alone. They need partners who understand the complex realities of oncology and can deliver solutions that work in the real world.
That’s why we work in partnership with veterinary clinics and animal pharmaceutical developers to ensure the next generation of advanced therapies can be transported and administered safely and effectively.
Supporting the Future of Oncology
Pet Cancer Awareness Month is a time to reflect and also to take action. At Cryoport Systems, we’re proud to support the researchers, manufacturers, and veterinary care teams who are transforming cancer care for companion animals. We know the road ahead is complex, but we also know that with the right logistics partner, it’s navigable.
Because the future of veterinary oncology doesn’t just depend on innovation, it depends on getting it there.
